398 related articles for article (PubMed ID: 28600210)
1. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
[TBL] [Abstract][Full Text] [Related]
2. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Velikova G; Morden JP; Haviland JS; Emery C; Barrett-Lee P; Earl H; Bloomfield D; Brunt AM; Canney P; Coleman R; Verrill M; Wardley A; Bertelli G; Ellis P; Stein R; Bliss JM; Cameron D;
Lancet Oncol; 2023 Dec; 24(12):1359-1374. PubMed ID: 37926100
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
4. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.
Untch M; Fasching PA; Konecny GE; von Koch F; Conrad U; Fett W; Kurzeder C; Lück HJ; Stickeler E; Urbaczyk H; Liedtke B; Salat C; Harbeck N; Müller V; Schmidt M; Hasmüller S; Lenhard M; Schuster T; Nekljudova V; Lebeau A; Loibl S; von Minckwitz G;
Ann Oncol; 2011 Sep; 22(9):1988-1998. PubMed ID: 21385882
[TBL] [Abstract][Full Text] [Related]
5. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
6. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Earl HM; Hiller L; Howard HC; Dunn JA; Young J; Bowden SJ; McDermaid M; Waterhouse AK; Wilson G; Agrawal R; O'Reilly S; Bowman A; Ritchie DM; Goodman A; Hickish T; McAdam K; Cameron D; Dodwell D; Rea DW; Caldas C; Provenzano E; Abraham JE; Canney P; Crown JP; Kennedy MJ; Coleman R; Leonard RC; Carmichael JA; Wardley AM; Poole CJ;
Lancet Oncol; 2017 Jun; 18(6):755-769. PubMed ID: 28479233
[TBL] [Abstract][Full Text] [Related]
7. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Ellis P; Barrett-Lee P; Johnson L; Cameron D; Wardley A; O'Reilly S; Verrill M; Smith I; Yarnold J; Coleman R; Earl H; Canney P; Twelves C; Poole C; Bloomfield D; Hopwood P; Johnston S; Dowsett M; Bartlett JM; Ellis I; Peckitt C; Hall E; Bliss JM; ;
Lancet; 2009 May; 373(9676):1681-92. PubMed ID: 19447249
[TBL] [Abstract][Full Text] [Related]
8. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
[TBL] [Abstract][Full Text] [Related]
9. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Del Mastro L; Poggio F; Blondeaux E; De Placido S; Giuliano M; Forestieri V; De Laurentiis M; Gravina A; Bisagni G; Rimanti A; Turletti A; Nisticò C; Vaccaro A; Cognetti F; Fabi A; Gasparro S; Garrone O; Alicicco MG; Urracci Y; Mansutti M; Poletti P; Correale P; Bighin C; Puglisi F; Montemurro F; Colantuoni G; Lambertini M; Boni L;
Lancet Oncol; 2022 Dec; 23(12):1571-1582. PubMed ID: 36370716
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Asola R; Kokko R; Ahlgren J; Auvinen P; Hemminki A; Paija O; Helle L; Nuortio L; Villman K; Nilsson G; Lahtela SL; Lehtiö K; Pajunen M; Poikonen P; Nyandoto P; Kataja V; Bono P; Leinonen M; Lindman H;
Lancet Oncol; 2009 Dec; 10(12):1145-51. PubMed ID: 19906561
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
13. Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.
Mattioli R; Gridelli C; Castellanos J; Duque A; Falcone A; Mansutti M; Bacon P; Lawrinson S; Skacel T; Casas A
Clin Transl Oncol; 2009 Dec; 11(12):842-8. PubMed ID: 20045791
[TBL] [Abstract][Full Text] [Related]
14. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.
Buzdar AU; Suman VJ; Meric-Bernstam F; Leitch AM; Ellis MJ; Boughey JC; Unzeitig G; Royce M; McCall LM; Ewer MS; Hunt KK;
Lancet Oncol; 2013 Dec; 14(13):1317-25. PubMed ID: 24239210
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Bear HD; Tang G; Rastogi P; Geyer CE; Liu Q; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2015 Sep; 16(9):1037-1048. PubMed ID: 26272770
[TBL] [Abstract][Full Text] [Related]
16. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.
Earl HM; Vallier AL; Hiller L; Fenwick N; Young J; Iddawela M; Abraham J; Hughes-Davies L; Gounaris I; McAdam K; Houston S; Hickish T; Skene A; Chan S; Dean S; Ritchie D; Laing R; Harries M; Gallagher C; Wishart G; Dunn J; Provenzano E; Caldas C;
Lancet Oncol; 2014 Feb; 15(2):201-12. PubMed ID: 24360787
[TBL] [Abstract][Full Text] [Related]
17. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ;
N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759
[TBL] [Abstract][Full Text] [Related]
18. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Cunningham D; Stenning SP; Smyth EC; Okines AF; Allum WH; Rowley S; Stevenson L; Grabsch HI; Alderson D; Crosby T; Griffin SM; Mansoor W; Coxon FY; Falk SJ; Darby S; Sumpter KA; Blazeby JM; Langley RE
Lancet Oncol; 2017 Mar; 18(3):357-370. PubMed ID: 28163000
[TBL] [Abstract][Full Text] [Related]
19. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.
Untch M; von Minckwitz G; Konecny GE; Conrad U; Fett W; Kurzeder C; Lück HJ; Stickeler E; Urbaczyk H; Liedtke B; Beckmann MW; Salat C; Harbeck N; Müller V; Schmidt M; Hasmüller S; Lenhard M; Nekljudova V; Lebeau A; Loibl S; Fasching PA;
Ann Oncol; 2011 Sep; 22(9):1999-2006. PubMed ID: 21382868
[TBL] [Abstract][Full Text] [Related]
20. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
